Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term survival after local immunotherapy for malignant gliomas: a retrospective study with 20 years follow-up.

BMC immunology - 20 Dec 2024

Duan Hao, He Zhenqiang, Chen Zhenghe, Chen Yukun, Hu Wanming, Sai Ke, Zhang Xiangheng, Xia Jianchuan, Li Yongqiang, Liu Ranyi, Zou Chaowei, Chen Zhongping, Mou Yonggao

Abstract excerpt

PURPOSE: Immunotherapy is a promising treatment for cancers but should be optimized for malignant gliomas. Because of immune privilege feature of the brain, local administration of immunotherapy may be a promising strategy for malignant glioma treatment. Identification of patients who may benefit from local immunotherapy is essential. METHODS: We retrospectively reviewed the clinicopathological characteristics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Immunotherapy

Share to Immunotherapy, Adoptive

Share to Mutation

Share to Treatment Outcome

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 39707189
DOI: 10.1186/s12865-024-00676-2
PMCID: PMC11662448

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term survival after local immunotherapy for malignant gliomas: a retrospective study with 20 years follow-up.PMID 39707189Read ↗

Glioma targeted therapy: insight into future of molecular approaches.Semantic proximity Read ↗

Molecular and Clinical Determinants of Response to Immunotherapy in High-Grade GliomaSemantic proximity Read ↗

Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study.Semantic proximity Read ↗

NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in GlioblastomaSemantic proximity Read ↗

Gene Targets of CAR-T Cell Therapy for GlioblastomaSemantic proximity Read ↗

TIGIT Is Positively Associated with Advanced Human Glioma and Displays an Immunosuppressive MicroenvironmentSemantic proximity Read ↗

A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injectionSemantic proximity Read ↗

Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant gliomaSemantic proximity Read ↗

Against the Resilience of High-Grade Gliomas: Gene Therapies (Part II)Semantic proximity Read ↗

Integrin blocking peptide reverses immunosuppression in experimental gliomas and improves anti-PD-1 therapy outcomeSemantic proximity Read ↗

TIGIT is Positively Associated with Advanced Human Glioma and Displays an Immunosuppressive MicroenvironmentSemantic proximity Read ↗

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade GliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.